IL203926A - Solid forms containing n - (5-tert-butyl-isoxazole-3-ram) - n- {4- [7- (2-morpholine-4-ram-ethoxy) imidazo [2, 1 – b] [3, 1] Benzothiazole-2-ram] phenyl} urea, their composition and uses - Google Patents

Solid forms containing n - (5-tert-butyl-isoxazole-3-ram) - n- {4- [7- (2-morpholine-4-ram-ethoxy) imidazo [2, 1 – b] [3, 1] Benzothiazole-2-ram] phenyl} urea, their composition and uses

Info

Publication number
IL203926A
IL203926A IL203926A IL20392610A IL203926A IL 203926 A IL203926 A IL 203926A IL 203926 A IL203926 A IL 203926A IL 20392610 A IL20392610 A IL 20392610A IL 203926 A IL203926 A IL 203926A
Authority
IL
Israel
Prior art keywords
benzothiazol
isoxazol
morpholin
imidazo
ethoxy
Prior art date
Application number
IL203926A
Other languages
English (en)
Hebrew (he)
Original Assignee
Ambit Biosciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambit Biosciences Corp filed Critical Ambit Biosciences Corp
Publication of IL203926A publication Critical patent/IL203926A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
IL203926A 2007-09-19 2010-02-11 Solid forms containing n - (5-tert-butyl-isoxazole-3-ram) - n- {4- [7- (2-morpholine-4-ram-ethoxy) imidazo [2, 1 – b] [3, 1] Benzothiazole-2-ram] phenyl} urea, their composition and uses IL203926A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99463507P 2007-09-19 2007-09-19
PCT/US2008/010884 WO2009038757A2 (en) 2007-09-19 2008-09-19 Solid forms comprising n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith

Publications (1)

Publication Number Publication Date
IL203926A true IL203926A (en) 2016-02-29

Family

ID=40468693

Family Applications (1)

Application Number Title Priority Date Filing Date
IL203926A IL203926A (en) 2007-09-19 2010-02-11 Solid forms containing n - (5-tert-butyl-isoxazole-3-ram) - n- {4- [7- (2-morpholine-4-ram-ethoxy) imidazo [2, 1 – b] [3, 1] Benzothiazole-2-ram] phenyl} urea, their composition and uses

Country Status (20)

Country Link
US (2) US8883783B2 (OSRAM)
EP (1) EP2201018B1 (OSRAM)
JP (1) JP5462168B2 (OSRAM)
KR (2) KR20150104231A (OSRAM)
CN (1) CN101868465B (OSRAM)
AR (1) AR068528A1 (OSRAM)
AU (1) AU2008302744B2 (OSRAM)
BR (1) BRPI0816904B8 (OSRAM)
CA (1) CA2696776C (OSRAM)
CY (1) CY1117583T1 (OSRAM)
DK (1) DK2201018T3 (OSRAM)
ES (1) ES2573292T3 (OSRAM)
HR (1) HRP20160520T1 (OSRAM)
HU (1) HUE027982T2 (OSRAM)
IL (1) IL203926A (OSRAM)
MX (1) MX2010002295A (OSRAM)
PL (1) PL2201018T3 (OSRAM)
SI (1) SI2201018T1 (OSRAM)
TW (1) TWI437988B (OSRAM)
WO (1) WO2009038757A2 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI409267B (zh) * 2006-03-17 2013-09-21 Ambit Biosciences Corp 治療疾病用之咪唑并噻唑化合物
KR20150104231A (ko) 2007-09-19 2015-09-14 암비트 바이오사이언시즈 코포레이션 Ｎ-(5-ｔｅｒｔ-부틸-이속사졸-3-일)-Ｎ''-[4-[7-(2-모르폴린-4-일-에톡시)이미다조[2,1-Ｂ][1,3]벤조티아졸-2-일]페닐]우레아를 포함하는 고체 형태, 그의 조성물 및 그의 용도
US7968543B2 (en) * 2007-11-08 2011-06-28 Ambit Biosciences Corporation Methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease
NZ595382A (en) 2009-03-23 2014-02-28 Ambit Biosciences Corp Combination therapy involving n-(5-(tert-butyl-isoxazol-3-yl)-n’-{ 4-(7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl} urea
SMT202000092T1 (it) 2009-05-14 2020-05-08 Ambit Biosciences Corp Formulazione essiccata a spruzzo o liofilizzata di ac220
WO2011056764A1 (en) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
CN104447801A (zh) 2009-11-05 2015-03-25 埃姆比特生物科学公司 用于制备咪唑并[2,1-b][1,3]苯并噻唑衍生物的方法
CN103172648B (zh) * 2011-12-20 2016-05-25 上海迪诺医药科技有限公司 三杂环衍生物、制备方法及应用
JP6116847B2 (ja) 2012-10-01 2017-04-19 アムビト バイオサイエンシス コーポレーションＡｍｂｉｔ Ｂｉｏｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ シクロデキストリンとの混合体を含有する錠剤
CN104513258B (zh) * 2013-09-26 2018-04-03 广东东阳光药业有限公司 取代脲衍生物及其在药物中的应用
CA2976752C (en) 2015-02-20 2019-12-17 Daiichi Sankyo Company, Limited Method for treating cancer by combined use
CN109251181B (zh) * 2017-07-13 2021-08-31 广东东阳光药业有限公司 取代脲衍生物的盐及其在药物中的应用
CN110763544A (zh) * 2019-09-20 2020-02-07 南京聚谱检测科技有限公司 一种激光剥蚀样品制靶用快干可精磨粘合剂
CN111413421A (zh) * 2020-02-20 2020-07-14 广东电科院能源技术有限责任公司 污泥燃烧后灰尘中氯离子含量的测试方法、控制方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL129432C (OSRAM) * 1964-02-29
NL129626C (OSRAM) * 1964-04-08
US3210370A (en) * 1964-06-22 1965-10-05 Upjohn Co Process for preparing 2, 2'-methylene-bisareneimiazoles
FR2463774A1 (fr) * 1979-08-21 1981-02-27 Yamanouchi Pharma Co Ltd Derives du 2-phenylimidazo(2,1-b)benzothiazole
US4354970A (en) * 1980-03-07 1982-10-19 Eastman Kodak Company Indoline coupled isothiazole azo dyes
JPS56138196A (en) 1980-03-29 1981-10-28 Yamanouchi Pharmaceut Co Ltd Imidazo (2,1-b)benzothiazole derivative
JPS5740492A (en) 1980-08-22 1982-03-06 Yamanouchi Pharmaceut Co Ltd Novel 2-phenylimidazo 2,1-b benzothiazole derivative
JPS57149288A (en) 1981-03-12 1982-09-14 Yamanouchi Pharmaceut Co Ltd Imidazo(2,1-b)benzothiazole derivative
JPS58109491A (ja) * 1981-12-23 1983-06-29 Yamanouchi Pharmaceut Co Ltd ２−フエニルイミダゾ〃２，１−ｂ「あ」ベンゾチアゾ−ル誘導体
US4464384A (en) 1981-12-23 1984-08-07 Yamanouchi Pharmaceutical Co., Ltd. 2-Phenylimidazo[2,1-b]benzothiazole compounds, salts thereof, process of producing them, and pharmaceutical compositions containing them
US5236952A (en) * 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
US4880824A (en) * 1987-09-21 1989-11-14 Ortho Pharmaceutical Corporation Phenyl and benzoyl substituted imidazo-fused heterocyclic calcium channel blockers
EP0524055A1 (fr) 1991-07-19 1993-01-20 Synthelabo Dérivés d'imidazo[2,1-b]benzothiazole-3-acétamide, leur préparation et leur application en thérapeutique
JPH05107705A (ja) 1991-10-17 1993-04-30 Konica Corp 新規な写真用カプラー
ES2126636T3 (es) * 1992-05-19 1999-04-01 Adir Derivados del bencimidazol con actividad antidiabetica y antiagregante plaquetaria.
FR2699920B1 (fr) 1992-12-24 1995-02-10 Synthelabo Dérivés d'imidazo [2,1-b] benzothiazole-3-acétamide, leur préparation et leur application en thérapeutique.
EP0607076A1 (fr) * 1993-01-15 1994-07-20 Synthelabo Dérivés de 9h-imidazo 1,2-a benzimidazole-3-acétamide à activité GABA
FR2700546B1 (fr) 1993-01-15 1995-02-17 Synthelabo Dérivés d'imidazo[2,1-b]benzoxazole-3-acétamide, leur préparation et leur application en thérapeutique.
JPH07291976A (ja) 1994-04-27 1995-11-07 Otsuka Pharmaceut Factory Inc イミダゾ〔２，１−ｂ〕チアゾール誘導体
FR2722501B1 (fr) 1994-07-13 1996-08-09 Synthelabo Derives de 9h-imidazo(1,2-a)benzimidazole-3-acetamide, leur preparation et leur application en therapeutique
JP3178843B2 (ja) * 1995-03-13 2001-06-25 日研化学株式会社 イミダゾチアゾール化合物
WO1998006724A1 (en) 1996-08-09 1998-02-19 Yamanouchi Pharmaceutical Co., Ltd. Metabotropic glutamate receptor agonists
US6127387A (en) 1996-12-10 2000-10-03 Thomas Jefferson University Use of CD4-binding small molecules to inhibit immune responses
FR2759698B1 (fr) 1997-02-20 1999-03-19 Synthelabo Derives de 1,4-diphenylimidazole-5-acetamide, leur preparation et leur application en therapeutique
JPH11106340A (ja) 1997-10-02 1999-04-20 Sumitomo Pharmaceut Co Ltd Ｓｔａｔ６活性化阻害剤
JP4437270B2 (ja) 1997-12-22 2010-03-24 バイエル コーポレイション 置換複素環式尿素を用いたｒａｆキナーゼの阻害
DE19805117A1 (de) 1998-02-09 1999-08-12 Bayer Ag Neue Oxazolidinone mit azolhaltigen Tricyclen
DE19905278A1 (de) 1999-02-09 2000-08-10 Bayer Ag Oxazolidinone und ihre Verwendung als antibakterielle Mittel
GB2351081A (en) 1999-06-18 2000-12-20 Lilly Forschung Gmbh Pharmaceutically active imidazoline compounds and analogues thereof
JP2001048786A (ja) 1999-08-05 2001-02-20 Yamanouchi Pharmaceut Co Ltd 三環式ヘテロアリール誘導体
DE19948434A1 (de) 1999-10-08 2001-06-07 Gruenenthal Gmbh Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
JP2001192386A (ja) 1999-10-29 2001-07-17 Meiji Seika Kaisha Ltd 新規トリアゾール誘導体及びこれを有効成分とする抗真菌剤
DE10019714A1 (de) * 2000-04-20 2002-01-10 Gruenenthal Gmbh Salze von bicyclischen, N-acylierten Imidazo-3-aminen und Imidazo-5-aminen
AU2001278875B2 (en) * 2000-07-06 2007-06-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tetrahydrobenzothiazole analogues as neuroprotective agents
US6696441B1 (en) * 2000-08-11 2004-02-24 The Regents Of The University Of California Inhibition of p53-induced stress response
US7601846B2 (en) * 2001-06-26 2009-10-13 The Regents Of The University Of California Compounds having activity as inhibitors of apoptosis
WO2003031587A2 (en) 2001-10-09 2003-04-17 The Regents Of The University Of California Use of stat-6 inhibitors as therapeutic agents
US20040127719A1 (en) * 2002-03-08 2004-07-01 Kexin Yang Alpha-isocyanocarboxylate solid support templates, method of preparation and for using the same
AR040661A1 (es) * 2002-07-26 2005-04-13 Theravance Inc Diclorhidrato cristalino de n-{2-[-((r)-2-hidroxi-2-feniletilamino)fenil]etil}-(r)-2hidroxi-2-(3-formamido-4-hidroxifenil)etilamina, agonista del receptor adrenergico beta 2
CA2506796A1 (en) 2002-11-25 2004-06-10 Pharmacia Corporation Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors
AU2003297153B2 (en) 2002-12-18 2010-06-10 Mallinckrodt Inc. Synthesis of heteroaryl acetamides
KR100647583B1 (ko) * 2003-10-07 2006-11-17 삼성에스디아이 주식회사 이미다졸 고리 함유 화합물 및 이를 이용한 유기 전계발광 소자
US7750160B2 (en) * 2003-11-13 2010-07-06 Ambit Biosciences Corporation Isoxazolyl urea derivatives as kinase modulators
TWI409267B (zh) * 2006-03-17 2013-09-21 Ambit Biosciences Corp 治療疾病用之咪唑并噻唑化合物
KR20150104231A (ko) 2007-09-19 2015-09-14 암비트 바이오사이언시즈 코포레이션 Ｎ-(5-ｔｅｒｔ-부틸-이속사졸-3-일)-Ｎ''-[4-[7-(2-모르폴린-4-일-에톡시)이미다조[2,1-Ｂ][1,3]벤조티아졸-2-일]페닐]우레아를 포함하는 고체 형태, 그의 조성물 및 그의 용도
US7968543B2 (en) * 2007-11-08 2011-06-28 Ambit Biosciences Corporation Methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease

Also Published As

Publication number Publication date
SI2201018T1 (sl) 2016-09-30
CA2696776C (en) 2015-12-15
US9585892B2 (en) 2017-03-07
KR20150104231A (ko) 2015-09-14
CN101868465B (zh) 2013-12-25
DK2201018T3 (en) 2016-05-17
EP2201018B1 (en) 2016-03-16
HUE027982T2 (en) 2016-11-28
AU2008302744A1 (en) 2009-03-26
ES2573292T3 (es) 2016-06-07
JP5462168B2 (ja) 2014-04-02
MX2010002295A (es) 2010-03-22
AU2008302744B2 (en) 2014-01-30
BRPI0816904A2 (pt) 2015-03-17
KR101572701B1 (ko) 2015-11-27
BRPI0816904B8 (pt) 2021-12-07
BRPI0816904B1 (pt) 2021-08-10
WO2009038757A3 (en) 2009-05-28
US20150238499A1 (en) 2015-08-27
CN101868465A (zh) 2010-10-20
TW200920360A (en) 2009-05-16
TWI437988B (zh) 2014-05-21
CY1117583T1 (el) 2017-04-26
PL2201018T3 (pl) 2016-11-30
CA2696776A1 (en) 2009-03-26
ES2573292T9 (es) 2016-07-08
AR068528A1 (es) 2009-11-18
EP2201018A2 (en) 2010-06-30
US8883783B2 (en) 2014-11-11
JP2010539237A (ja) 2010-12-16
HRP20160520T1 (hr) 2016-07-29
US20090131426A1 (en) 2009-05-21
KR20100061734A (ko) 2010-06-08
WO2009038757A2 (en) 2009-03-26

Similar Documents

Publication Publication Date Title
IL203926A (en) Solid forms containing n - (5-tert-butyl-isoxazole-3-ram) - n- {4- [7- (2-morpholine-4-ram-ethoxy) imidazo [2, 1 – b] [3, 1] Benzothiazole-2-ram] phenyl} urea, their composition and uses
SG10201401826TA (en) Formulation comprising metformin and vildagli ptin
IL190228A0 (en) Phenyl-and pyridyl-1,2,4-oxadiazolone derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals
IL212308A0 (en) Solid forms of n-(4-(7-azabicyclo[2.2.1] heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide and compositions comprising the same and uses thereof
PL2205244T3 (pl) Sposoby podawania N-(5-tert-butylo-izoksazol-3-ilo)-N’-{4-[7-(2-morfolin-4-ylo-etoksy)-imidazo-[2,1-b]-[1,3]-benzotiazol-2-ilo]-fenylo} mocznika do leczenia chorób proliferacyjnych
EG25201A (en) 4-cyclopropyl-1,2,3- thiadiazole compound, agrohorticultural plant disease controlling agent and method of using the same
WO2007034196A3 (en) Imaging agents comprising silicon
LTPA2017031I1 (lt) 8-[{1-(3,5-Bis-(trifluormetil) fenil) -etoksi}-metil]-8-fenil-1,7-diaza-spiro[4.5]dekan-2-ono hidrochlorido druska ir jos gamybos būdas
DK1555267T3 (da) 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLER
ZA200710342B (en) The preparation and use of compounds as aspartyl protease inhibitors
ZA200707531B (en) N-(N-Sulfonylaminomethyl) cyclopropanecarboxamide derivatives useful for the treatment of pain
NI201200072A (es) Métodos y composiciones para tratar cáncer
ZA200705209B (en) Methods for enhancing the palatability of compositions for consumption by animals
NO20084270L (no) Anvendelse av imidazo[2,1-b] -1,3,4-tiadiazol-2-sulfonamidforbindelser for behandling av nevropatisk smerte
IL192328A (en) Walls of yeast cells for the treatment and protection of plants against diseases caused by pathogenic factors and compounds containing these walls of yeast cells
TW200613479A (en) Coating formulation having improved rheological properties
ZA200801896B (en) Slow-release composition, method for the preparation thereof, and use of the same
BRPI0810323A2 (pt) "combinação de ácido pirrolidona 5-carboxílico, uso do ácido pirrolidona 5-carboxílico, composição e seu uso"
EP1954685A4 (en) FUROXANE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
AU2006321904A8 (en) 1, 1, 3-trioxo-1 , 2 , 5-thiadiazolidines and their use as PTP-ases inhibitors
EP1673384A4 (en) NITROSED GLUTAMIC ACID COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF USE
PL1902050T3 (pl) Pochodne oksazolidynonu i ich zastosowanie jako antybiotyki
ZA200900207B (en) Aminoalcohol derivative and immunosuppressant containing the same as active ingredient
ZA201000987B (en) Solid forms comprising n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith
WO2006124770A3 (en) Treatment of sepsis and inflammation with alpha2a adrenergic antagonists

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed